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Abstract Öz 
Purpose: Long QT Syndrome (LQTS) is characterized by 
prolonged ventricular repolarization and tendency to 
malignant tachyarrhythmia. We reported 16 patient 
diagnosed congenitally LQTS as a tertiary centre's 12 years 
experience.  
Material and Methods: Patients whom diagnosed as 
congenitally LQTS in Cukurova University Divison of 
Pediatric Cardiology between years 2001 to 2013 were 
included the study. 
Results: Sixteen patients (6 female, 12 male) were 
diagnosed as congenitally LQTS. Mean age of patients  
was 10 years (2.6-20 years), mean follow up period was 35 
months (11-120 months). Mean corrected QT interval was 
measured 520 ms (470-590 ms). At the diagnosis nine of 
sixteen patients (56%) had syncope, convulsion or cardiac 
arrest history, and three of them were misdiagnosed as 
epilepsy and were treated with antiepileptic drugs as well. 
Conclusion: We want to underline the importance of 
electrocardiography monitoring at all family members and 
some patients who misdiagnosed as recurrent seizures. 
Amaç: Uzun QT Sendromu (LQTS) uzamış ventriküler 
repolarizasyon zamanı ve malign taşikardiye eğilim ile 
karakterizedir. Bu yazıda doğumsal LQTS tanısı almış 16 
hastamızda 12 yıllık deneyimimizi sunduk.  
Gereç ve Yöntem: Çalışmamızda Çukurova Üniversitesi 
Pediatrik kardiyoloji bölümünde 2001-2013 yılları arasında 
konjenital olarak LQTS tanısı alan hastalar dahil edildi. 
Bulgular: 16 hastaya (6 kadın, 12 erkek) konjenital LQTS 
tanısı konuldu. Hastaların ortalama yaşı 10 (2.6-20 yaş) 
ortalama takip süresi ise 35 ay idi (11-120 ay). Ortalama 
doğrulanmış QT intervali 520 ms (470-590 ms) olarak 
ölçüldü. Teşhis esnasında onaltı hastadan dokuzunda 
senkop, konvülsiyon veya kalp krizi hikayesi varken üç 
hastaya yanlış epilepsi teşhisi konarak antiepiletik ilaçlarla 
tedavi edilmiş. 
Sonuç: Özellikle tüm aile bireylerinde yüzeyel EKG 
taramasının önemini ve bazen hastaların yanlış tanı alarak 
tekrarlayan dirençli nöbet olarak tedavi edildiklerini 
vurgulamak istedik. 
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INTRODUCTION 
Long QT Syndrome (LQTS) is an inherited disorder 
characterized by prolonged ventricular 
repolarization (QT interval prolongation) and a 
propensity for syncope and sudden death secondary 
to malignant polymorphic ventricular 
tachyarrhythmia such as Torsades de pointes.  
Mutation of one of several genes lie behind this 
situation. These mutations tend to prolong the 
duration of the ventricular action potential, thus 
lengthening the QT interval.  
LQTS remains an underdiagnosed disorder, because 
at least 10-15% of LQTS gene carriers have a 
normal QTc duration. The prevalence of LQTS is 
about 1 in 10000 individuals1. Episodes may lead to 
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palpitations, fainting, syncope and sudden death that 
provoked by various stimuli like during exercise, 
emotional stress, at rest, or at sleep depending on 
the type of mutation. Most important feature of 
LQTS is to be a leading cause of sudden death in 
children and adolescents. Excellent outcomes in the 
management of LQTS can be achieved with lifestyle 
modifications and therapeutic intervention, 
highlighting the importance of its identification. 
Although genetic testing remains the diagnostic gold 
standard, the diagnosis of LQTS remains 
challenging when electrocardiographic findings are 
borderline, which can occur in up to 50% of cases2. 
This occurrence emphasizes the importance of 
diagnosing LQTS in the presymptomatic period. 
Resting 12-lead ECG and routine exercise testing is 
useful in predicting and directing genetic testing in 
LQTS3. Patient and family education about the 
nature of LQTS and avoidance of triggering factors 
are important. In this current paper we reported 
twelve  years clinical experience with congenital 
LQTS in a tertiary Pediatric Cardiology Department. 
MATERIAL AND METHODS 
Patients whom diagnosed as congenitally LQTS in 
Cukurova University Divison of Pediatric 
Cardiology between years 2001 to 2013 were 
included the study. Inclusion criteria included a 
history of syncope or cardiac arrest and either the 
presence of an affected first-degree relative or a 
borderline to prolonged corrected QT interval 
(≥440 ms in men and _≥460 ms in women) on their 
resting 12-lead ECG.  
The QT interval was measured as the time interval 
in milliseconds from the beginning of the QRS 
complex and the end of the T-wave. The QT 
interval was considered the longest interval of all 12 
leads, primarily measured in lead II and V5. The 
mean of 3 QT intervals was used. The corrected QT 
(QTc) was calculated using the Bazett formula. For 
men, the QTc was considered normal if it was <440 
ms, borderline if 441 to 460 ms, and prolonged if 
≥460 ms. For women, a QTc of _<460 ms, 461 to 
480 ms, and ≥480 ms was defined as normal, 
borderline, and prolonged, respectively4.  
Family histories were questioned to all patients. β-
Blockers were recommended to all patients with a 
new diagnosis of LQTS, regardless of symptom 
status. β-Blocker use was predominantly propranolol 
at a daily dosage of 2 to 3 mg/kg, targeting a 30 beat 
per minute reduction in peak treadmill heart rate at 
peak work load5. If this heart rate change was not 
achieved, the dose was increased and testing was 
repeated. As all data was acquired during routine 
clinical care, no informed consent was required. 
Statistical analysis  
Statistical analyses were performed using SPSS 
software version 17. Descriptive analyses were 
presented using mean ±SD, median (min-max 
value), and percentages were expressed where 
appropriate. 
RESULTS  
Sixteen patients  (6 female, 12 male) were diagnosed 
as congenitally LQTS. Mean age of patients  was 10 
years (2.6 - 20 years), mean follow up period was 35 
months (11-120 months). Mean corrected QT 
interval was measured 520 ms (470-590 ms). At the 
diagnosis nine of sixteen patients (56%) had 
syncope, convulsion or cardiac arrest history, and 
three of them were misdiagnosed as epilepsy and 
were treated with antiepileptic drugs as well. 
Implantable Cardioverter Defibrillator (ICD) was 
implanted two patients with high risk. One of them 
was ten-year-old female with recurrent syncope 
attacks due to documented ventricular 
tachyarrhythmia, and the other was sixteen-year-old 
male patient that long pauses and bradyarrhythmia 
was documented on his 24 hours Holter ECG 
monitoring, also there was a sudden cardiac death 
history at his family.  
Beta-blockade medication was admitted to all 
patients at diagnosis, and then maintenance dose 
adjustment was made through heart rate response to 
treadmill exercise test. Female patient that whom 
required ICD implantation was diagnosed as LQT3 
later on follow up. She was prone to syncope during 
inactive periods and pause depended VT was 
documented. At first a VVIR pacemaker implanted, 
then high dosage propranolol therapy started safely. 
Because LQT3 is a disorder of sodium channel, oral 
Mexiletin was added.  
When the pacemaker generator reached to the end 
of life, and the size of the patient was suitable for 
ICD, the device upgraded to an ICD. Family 
histories were questioned to all patients; there were 
seven patients (47% of all) with positive family 
history for sudden cardiac arrest. No cardiac arrest 
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event was observed at our patients during twelve 
year period. Two patients’ asymptomatic first degree 
relatives were diagnosed LQTS on family ECG 
screening. Characteristics of patients were 
summarized in the Table 1. 
Table 1. Characteristics of patients  
Patient Age 
(year) 
Follow up 
(month) 
QTc* 
(msn) 
Symptom SCA† 
history in 
family 
Propranolol 
first dose 
kg/mg 
Propranolol 
maintenance 
dose (kg/mg) 
1 8.7 19 0.58 Cardiac 
arrest 
Absent 2 4 
2 8.8 13 0.49 Absent Present 1,5 2 
3 9.1 21 0.48 Absent Present 2 2 
4 10,1 67 0.47 Syncope Absent 2 2 
5 5,1 24 0.50 Absent Absent 2 2 
6 10 17 0.58 Syncope Present 1,4 1.4 
7 10 36 0.51 Syncope Absent 2 2.7 
8 10 18 0.49 Syncope Absent 2 2.8 
9 11.3 84 0.50 Absent Absent 1.5 1.5 
10 8.6 13 0.53 Syncope Present 2 3 
11 20 120 0.51 Absent Present 2 2 
12 7.3 13 0.58 Absent Present 2 2 
13‡ 16 17 0.59 Syncope Present 2 3 
14 13 17 0.48 Absent Absent 2 2 
15 2.6 11 0.50 Syncope Absent 2 3 
16‡ 10 72 0.56 Syncope Absent 2 3 
* QTc; corrected QT intervale, † SCA; sudden cardiac arrest,‡ ICD implanted patients 
 
DISCUSSION  
Congenital Long-QT syndrome is a significant cause of 
cardiovascular mortality, especially in structurally 
normal hearts. Mutation in at least twelve genes 
have been identified thus far in patients with genetic 
LQTS; the distinct genetic types are designated 
LQTS 1 through 12. The first three, LQTS1-3, are 
the most prevalent and most studied6. The diagnosis 
of LQTS is clear-cut when there is a marked 
prolongation of the QTc interval with a positive 
family history of the syndrome. In the absence of 
genetic screening, the diagnosis is often measured in 
probabilities. Schwartz and colleagues refined the 
diagnostic criteria in 1993 and then revised4,5. The 
diagnosis of LQTS was made according to QTc 
measurements at 12 lead ECG, clinical symptoms 
and family history in this current study. 
Once the diagnosis has been made, the next step is 
to determine the patient’s risk of malignant 
arrhythmias. Prior et al reported risk stratification 
on LQTS and QTc longer than 500 ms was found 
the single most powerful predictor of events7. Prior 
cardiac arrest,  syncope  with  triggering  factor on 
beta-blockade therapy, and recent syncope with 
QTc>500 ms were determined as the highest risk 
factors.  
Eleven patients’ (68%) QTc interval was longer than 
500 ms in this serial and one patient was aborted 
cardiac arrest before. Beta-blocker agents are 
advised for the probands and affected family 
members in general management of LQTS. If a 
patient experience further syncope or aborted 
cardiac arrest on beta-blocker therapy, ICD 
implantation is recommended8,9. Two patients were 
determined as the highest risk group because one of 
them had recurrent syncope attacks, and the other 
had significant bradyarrhythmias on Holter ECG 
with a history of sudden cardiac arrest family 
member. ICD were implanted to these two patients. 
The remaining patients with QTc longer than 500 
ms and one patient with aborted cardiac arrest 
history did not experience a new event on beta-
blocker therapy. Maintenance dose of beta-blockade 
agent was determined as patients’ response to 
adrenalin stimuli during Treadmill exercise test. 
Convulsive syncope due to arrhythmias from QT 
prolongation is sometimes misinterpreted as a 
seizure10. Three patients whom misdiagnosed as 
epilepsy were treated with antiepileptic drugs as well. 
Antiepileptic drugs were discontinued after beta-
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blockade therapy and no convulsive syncope was 
observed subsequently. Another important point to 
draw attention to this situation is some antiepileptic 
drugs may induce QT prolongation. Patients and 
family members education about nature of LQTS 
and critical importance of medical treatment with 
beta-blockers is essential. Also education about 
avoidance of medication that induces QT 
prolongation is important. Recommendation 
examples about triggering factors are, avoidance of 
alarm clocks in patients with LQTS2, and restriction 
of physical activity (particularly swimming) in those 
with LQT1. 
A recommendation for genetic testing in LQTS is 
controversial. Comprehensive genetic testing for 
LQTS is definitely indicated in probands with 
definitive LQTS. Family member screening to 
definitive LQTS patient is crucial. Measurement of 
QTc on basal 12-lead ECG is useful for screening. 
But ECG is not useful at silent carriers that who 
have mutation on LQT1 but normal QTc. Silent 
carriers have lower risk of cardiac events but not 
zero. This is an important point to draw attention 
for genetic screening of family members of 
symptomatic individuals, even if the family members 
have normal ECG. All patients’ family members 
were screened with basal ECG, and they were 
questioned about palpitation, syncope, aborted 
cardiac arrest. Two patients’ asymptomatic first 
degree relatives were diagnosed LQTS on family 
screening and beta-blockade therapy was admitted. 
There were seven patients (two of them are siblings) 
with history of sudden cardiac arrest family member, 
and this was the remarkable result. 
Congenital long QT syndrome should be suspected 
with presence of QT prolongation and characteristic 
T abnormalities on surface ECG and with history of 
syncope, epilepsy especially resistant to drugs and 
aborted cardiac arrest in the patient or patient’s 
family. Beta-blockade agent is beneficial for most of 
LQTS subtype. Implantation of ICD is appropriate 
for high risky patients. Family members’ ECG 
screening is crucial. Genetic screening to 
symptomatic individuals’ family members with 
normal ECG is recommended. Education of 
patients and family members, avoidance of 
triggering factors are critical point of the 
management.    
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